C030046I01Rik Activators
R3H domain-containing protein 4 (R3HDM4) Activators comprise a series of chemical compounds that indirectly amplify the functional activity of R3HDM4 by modulating various signaling pathways. Forskolin acts upstream, enhancing cAMP levels which activate PKA; this catalyzes a signaling cascade that culminates in transcriptional changes increasing R3HDM4 activity. Compounds like Epigallocatechin gallate (EGCG), through kinase inhibition, and PI3K inhibitors LY294002 and Wortmannin, decrease competitive signaling, thus indirectly promoting an environment where R3HDM4 is more active. Furthermore, the inhibition of specific MAPK pathways by SB203580 and U0126 could shift the signaling balance towards enhancing R3HDM4 activity due to the interconnectivity of signaling networks. Additionally, Sphingosine-1-phosphate (S1P) and the calcium ionophore A23187 (Calcimycin) regulate sphingolipid and calcium signaling, respectively, which may result in transcriptional changes that lead to increased R3HDM4 activity.
On the other hand, Phorbol 12-myristate 13-acetate (PMA) activates PKC, which can have widespread effects on signaling pathways, including those that enhance the activity of R3HDM4. The kinase inhibitory actions of Staurosporine, although broad, might selectively promote R3HDM4-associated pathways by suppressing kinases that negatively regulate these pathways. Thapsigargin, by increasing intracellular calcium levels, activates calcium-dependent signaling that can lead to enhanced R3HDM4 activity. Lastly, Genistein's inhibition of tyrosine kinases may diminish competitive interference in signaling pathways, allowing for increased activation of pathways associated with R3HDM4, thus indirectly enhancing its functional activity within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which can influence multiple signaling pathways. One of the downstream effects of PKC activation is the modulation of transcription factors that can lead to the enhanced expression and activity of R3HDM4. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a kinase inhibitor that can lead to the reduction of competitive signaling pathways, thereby indirectly increasing the functional activity of R3HDM4 through the relief of inhibitory pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents the phosphorylation and activation of AKT. This modulation of the PI3K/AKT pathway can lead to the alteration of transcriptional programs that upregulate R3HDM4 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can shift cellular signaling to favor pathways that may upregulate R3HDM4 due to the interconnected nature of signaling networks, thereby enhancing its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that suppresses the MAPK/ERK pathway. Inhibition of MEK can result in the upregulation of alternative signaling pathways that may enhance the activity of R3HDM4. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P modulates sphingolipid signaling pathways, which can influence transcription factors and gene expression profiles, potentially leading to the upregulation and enhanced activity of R3HDM4. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels, activating calcium-dependent signaling pathways. This can lead to the activation of transcriptional programs that enhance the activity of R3HDM4. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor that can block AKT activation, leading to changes in downstream signaling that positively influence the functional activity of R3HDM4 through indirect pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor, which can lead to the selective activation of signaling pathways associated with R3HDM4 by inhibiting kinases that negatively regulate these pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased intracellular calcium levels. The resultant calcium signaling can enhance R3HDM4 activity by affecting related transcriptional responses. | ||||||